Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there.

Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.

Historical evidence indicates that abrupt market fluctuations can affect any corporation, regardless of its perceived dominance.

Eli Lilly and Company earnings beat lifts stock: revenue/EPS beat guidance, and the 2026 outlook looks strong, but watch ...

Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.

The stock price has climbed in the triple digits over three years.

Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s ...

Eli Lilly's stock surged Wednesday while shares of weight-loss rival Novo Nordisk slumped, widening the gap between the drugmakers.

Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.

Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 26.12% on an annualized basis producing an average annual return of 38.25%. Currently, Eli Lilly and Co has a market ...

Eli Lilly stock jumps 8% after Q4 earnings beat. Revenue hits $19.3B driven by Mounjaro and Zepbound sales growth.

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...